{"certainAgreement":{"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission for publication/presentation.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Inclusion of multiple tumor types and several dose levels in monotherapy and combination with nivolumab limits the ability to accurately evaluate the incidence of off-target effects adverse events."},"pointOfContact":{"email":"helen.collins@fiveprime.com","organization":"Five Prime Therapeutics","phone":"650-745-9633","title":"Helen Collins, Chief Medical Officer"}}